Wetherby Asset Management Inc. grew its holdings in shares of Allergan plc (NYSE:AGN) by 11.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,453 shares of the company’s stock after acquiring an additional 1,816 shares during the period. Wetherby Asset Management Inc.’s holdings in Allergan were worth $3,324,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in AGN. Dakota Wealth Management bought a new position in Allergan in the third quarter worth about $472,000. Nomura Asset Management Co. Ltd. raised its holdings in shares of Allergan by 1.0% during the third quarter. Nomura Asset Management Co. Ltd. now owns 127,784 shares of the company’s stock valued at $24,340,000 after buying an additional 1,320 shares during the last quarter. Harbour Capital Advisors LLC raised its holdings in shares of Allergan by 31.0% during the third quarter. Harbour Capital Advisors LLC now owns 6,584 shares of the company’s stock valued at $1,254,000 after buying an additional 1,558 shares during the last quarter. Sound Shore Management Inc. CT bought a new stake in shares of Allergan during the third quarter valued at approximately $140,026,000. Finally, Acorn Advisory Capital L.P. bought a new stake in shares of Allergan during the third quarter valued at approximately $610,000. Institutional investors own 78.40% of the company’s stock.

In other news, Director Joseph H. Boccuzi bought 900 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were purchased at an average price of $190.59 per share, with a total value of $171,531.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were purchased at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is owned by insiders.

A number of equities research analysts have recently weighed in on AGN shares. Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a report on Saturday, September 15th. Raymond James reaffirmed a “buy” rating and set a $232.00 price target (up previously from $211.00) on shares of Allergan in a report on Monday, September 17th. Zacks Investment Research cut Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $180.00 price target on shares of Allergan in a report on Friday, September 14th. Finally, ValuEngine raised Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $209.18.

Shares of NYSE:AGN opened at $163.86 on Tuesday. Allergan plc has a 12 month low of $142.81 and a 12 month high of $197.00. The company has a market cap of $55.83 billion, a P/E ratio of 10.02, a PEG ratio of 1.31 and a beta of 1.31. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.89 billion. During the same quarter in the previous year, the company earned $4.15 earnings per share. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. As a group, analysts anticipate that Allergan plc will post 16.42 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, November 9th. This represents a $2.88 annualized dividend and a yield of 1.76%. Allergan’s payout ratio is 17.61%.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/11/13/allergan-plc-agn-stake-increased-by-wetherby-asset-management-inc.html.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

See Also: How a Put Option Works

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.